Meeting
2019 Genitourinary Cancers Symposium
Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
Authors
Christophe Massard
Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France
Christophe Massard , Margitta Retz , Peter Hammerer , Fernando Quevedo , Peter C.C. Fong , William R. Berry , Howard Gurney , Josep M. Piulats , Anthony Joshua , Mark David Linch , Michael Kolinsky , Emanuela Romano , Srikala S. Sridhar , Henry Jacob Conter , Marinela Augustin , Haiyan Wu , Charles Schloss , Christian Heinrich Poehlein , Evan Y. Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02861573
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 170)
DOI
10.1200/JCO.2019.37.7_suppl.170
Abstract #
170
Poster Bd #
G13
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
First Author: Christophe Massard
Poster
2019 Genitourinary Cancers Symposium
Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
First Author: Peter C.C. Fong
Poster
2020 Genitourinary Cancers Symposium
KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: William R. Berry
Poster
2019 Genitourinary Cancers Symposium
Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Marcus Marie Moses